Systemic IL-12 Administration Alters Hepatic Dendritic Cell Stimulation CapabilitiesReportar como inadecuado

Systemic IL-12 Administration Alters Hepatic Dendritic Cell Stimulation Capabilities - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

The liver is an immunologically unique organ containing tolerogenic dendritic cells DC that maintain an immunosuppressive microenvironment. Although systemic IL-12 administration can improve responses to tumors, the effects of IL-12-based treatments on DC, in particular hepatic DC, remain incompletely understood. In this study, we demonstrate systemic IL-12 administration induces a 2–3 fold increase in conventional, but not plasmacytoid, DC subsets in the liver. Following IL-12 administration, hepatic DC became more phenotypically and functionally mature, resembling the function of splenic DC, but differed as compared to their splenic counterparts in the production of IL-12 following co-stimulation with toll-like receptor TLR agonists. Hepatic DCs from IL-12 treated mice acquired enhanced T cell proliferative capabilities similar to levels observed using splenic DCs. Furthermore, IL-12 administration preferentially increased hepatic T cell activation and IFNγ expression in the RENCA mouse model of renal cell carcinoma. Collectively, the data shows systemic IL-12 administration enables hepatic DCs to overcome at least some aspects of the inherently suppressive milieu of the hepatic environment that could have important implications for the design of IL-12-based immunotherapeutic strategies targeting hepatic malignancies and infections.

Autor: Tim Chan, Timothy C. Back, Jeffrey J. Subleski, Jonathan M. Weiss, John R. Ortaldo, Robert H. Wiltrout



Documentos relacionados